<DOC>
	<DOCNO>NCT01196208</DOCNO>
	<brief_summary>The purpose study provide option brentuximab vedotin treatment eligible patient study SGN35-005 C25001</brief_summary>
	<brief_title>A Treatment-Option Protocol Provide Brentuximab Vedotin Eligible Patients Completing Studies SGN35-005 C25001</brief_title>
	<detailed_description>The protocol amend reflect change phase 2/3 study expand access program ( EAP ) US would include patient ALCL HL . A later amendment allow patient CD30-positive cutaneous T-cell lymphoma enroll . Enrollment may continue patient may receive brentuximab vedotin treatment study drug commercially approve available patient geographic region .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Participated either SGN35005 C25001 clinical study experience progression . Patients receive brentuximab vedotin C25001 must objective response time discontinuation . Completed previous treatment radiation , chemotherapy , biologics and/or investigational agent least 4 week prior first dose brentuximab vedotin History another primary malignancy remission least 3 year Known cerebral/meningeal disease Peripheral neuropathy grade 2 great Females pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Disease , Hodgkin</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Monomethylauristatin E</keyword>
	<keyword>Lymphoma , Large-Cell , Anaplastic</keyword>
	<keyword>Lymphoma , T-Cell , Cutaneous</keyword>
	<keyword>Lymphoma , Non-Hodgkin</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>Antigens , CD30</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Immunotherapy</keyword>
</DOC>